Monoclonal Antibody Targeting Sialyl-di-Lewisa–Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential

Silvana T. Tivadar(University of Nottingham), Mireille Vankemmelbeke(University of Nottingham), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Tina Parsons(University of Nottingham), Richard S. McIntosh(University of Nottingham), Robert Moss(University of Nottingham), Jia Xin Chua(University of Nottingham), Lindy G. Durrant(University of Nottingham), Abed M. Zaitoun(GlaxoSmithKline (United Kingdom))
Molecular Cancer Therapeutics
December 23, 2019
10.1158/1535-7163.mct-19-0221
Cited by 27

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Faecal microbiota composition and host–microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome
|Gut|2013|340